[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"selinexor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:selinexor":15},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100559086","phase-1-selinexorpegaspargasedexamethasonein--nktcl-100559086",false,"NCT06559553","\"Selinexor+Pegaspargase+Dexamethasone\"in Ⅰ\u002FⅡ NKTCL","A Prospective Clinical Study of \"Selinexor+Pegaspargase+Dexamethasone\" in the Treatment of Stage Ⅰ\u002FⅡ NK\u002F T-Cell Lymphoma","Selinexor","Inclusion Criteria:\n\n1. Age 18-70 years old, ECOG score 0-2; (including those aged 18 and 70);\n2. Pre-survival time \\> 6 months;\n3. The pathological tissue was confirmed as NK\u002FT cell lymphoma (the pathological report of the first three months of enrollment could be accepted) (Note: If there is any doubt about the pathological diagnosis, domestic third-party consultation could be organized);\n4. Clinical stage Ⅰ to Ⅱ (CA stage) with at least one measurable lesion;\n5. Acceptable hematological indicators, no contraindications to chemotherapy; Neutrophil absolute value ≥1.0×10\\^9 \u002FL, platelet ≥75×10\\^9 \u002FL, hemoglobin ≥80g\u002FL (except patients with lymphoma bone marrow infiltration);\n6. Liver function: direct bilirubin ≤1.5× upper limit reference value; Glutamic pyruvic transaminase or glutamic oxalacetic transaminase ≤2.5× upper limit reference value; Alkaline phosphatase ≤3×ULN in non-bone invaded patients;\n7. Renal function: serum creatinine ≤1.5×ULN;\n8. Female and male patients of reproductive age and their spouses are willing to use adequate contraception throughout the study period, and female patients of reproductive age must have a negative serum pregnancy test within 7 days before the first dose;\n9. The newly treated patient had not received other tumor-related treatment in the past;\n10. Subjects voluntarily participate in the clinical trial, sign informed consent, and cooperate with follow-up;\n\nExclusion Criteria:\n\n1. Refuse to collect blood samples;\n2. Previous allergy to any of the drugs in the program;\n3. Pregnant and lactating women;\n4. Major diseases that the investigator believes can cause interference with the test;\n5. Combined with other tumors;\n6. There are contraindications related to therapeutic drugs in the program;\n7. Persons with serious mental illness;\n8. Participating in other clinical trials;\n9. Previous anti-tumor therapy (such as radiotherapy, chemotherapy, hormone therapy, biotherapy, immunotherapy);\n10. Other serious medical conditions that may limit participants\\' participation in the trial, such as uncontrolled diabetes; Severe cardiac insufficiency (NYHA grade II or above); Acute coronary syndrome within the last 6 months; Coronary revascularization such as stenting, coronary artery bypass surgery, and other heart and large vessel related procedures within the last 6 months; Severe arrhythmias include frequent ventricular early, ventricular tachycardia, rapid atrial fibrillation\u002Fflutter, and severe bradycardia. Uncontrolled hypertension: systolic blood pressure \\>150mmHg, diastolic blood pressure \\>100mmHg. Gastric ulcers (stomach ulcers that researchers have determined are at risk of perforation); Active autoimmune diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren\\'s syndrome, autoimmune thrombocytopenia, etc.); Severe respiratory disease (such as obstructive pulmonary disease and a history of bronchospasm);\n11. Hemophagic cell syndrome;\n12. Researchers do not consider it suitable for inclusion;\n13. Hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal reference value range; Hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA positive; Human immunodeficiency virus (HIV) antibody positive; Syphilis test positive.","ALL","18 Years","70 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","evaluate the efficacy and safety of \"Selinexor+pegaspargase+dexamethasone\" in early stage NK\u002F T-cell lymphoma",[29,15],"NKTCL",[29,15],"RECRUITING","2025-07-10",{"date":34,"type":35},"2025-07-14","ACTUAL",{"date":37,"type":35},"2024-09-01",{"date":39,"type":22},"2026-12-31",{"name":41,"class":42},"Mingzhi Zhang","OTHER"]